Rare disease

#Biotechnology #Cancer research #DDII #DDIIDigitalForum #Drug discovery #Investment #Rare disease #Technology #Tumours

This week in Drug Discovery (12-16 October)

News round-up for 12-16 October 2026 by Megan Thomas, Multimedia Editor at DDW.  This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Conference in London, as well as new initiatives to accelerate rare disease drug development, promising preclinical data for Duchenne muscular dystrophy, clinical trial… Read More

#News

FDA headquarters
#FDA #Rare disease #Regulatory

FDA launches initiative to accelerate rare disease drugs

The US Food and Drug Administration (FDA), a division within the US Department of Health and Human Services (HHS), has announced the Rare Disease Framework Initiative to accelerate the development of drugs and biologics for rare diseases.   According to the regulator, the initiative will develop an optimised, fit-for-purpose framework that… Read More

#News #Regulatory

Deal making
#Mergers and acquisitions #Neurodegenerative disorders #Rare disease #Shionogi

Shionogi expands rare disease portfolio with IntraBio buyout

Shionogi has announced plans to acquire IntraBio, a biopharmaceutical company developing therapies for neurodegenerative diseases, for $2 billion.  The transaction will add Aqneursa (levacetylleucine) and IntraBio’s capabilities in the rare disease area to Shionogi’s growing portfolio.  Aqneursa was approved by the FDA in September 2024 for neurological manifestations of Niemann-Pick… Read More

#Business & Investment #News

#CONNECTA Therapeutics #Funding #Phase II trial #Rare disease

€3.1 million to support Fragile X syndrome programme

CONNECTA Therapeutics has closed a €3.1 million financing led by new investor Clave Capital through its Innvierte Science Tech Clave Innohealth, FCR fund.  The funds will support CONNECTA in accelerating the Phase IIa clinical trial of CTH120 in adult males with Fragile X syndrome (FXS).  Jordi Fàbrega, Co‑Founder and CEO… Read More

#Business & Investment #News

#Antisense Oligonucleotides (ASOs) #Orphan drugs #Phase III trial #Rare disease #Ultragenyx

Ultragenyx’s ASO for Angelman Syndrome fails at Phase III

Ultragenyx Pharmaceutical has revealed that its Phase III Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve its primary endpoint of change from Baseline in Bayley-4 cognitive raw score.  The trial also failed to achieve the key secondary endpoint of net response in Multidomain Responder… Read More

#News

FDA
#FDA #Ionis Pharmaceuticals #Neurology #Rare disease

FDA approves first disease modifying treatment for Alexander disease

The US Food and Drug Administration (FDA) has approved Ionis Pharmaceuticals’ Zanvastro (zilganersen) for the treatment of Alexander disease (AxD) in paediatric and adult patients.   It is the first and only disease modifying treatment for AxD, an ultra-rare, progressive and often fatal neurological disorder that can affect motor, cognitive, autonomic… Read More

#News #Regulatory

#FDA #Gene therapy #Rare disease #Ultragenyx

FDA approves gene therapy for glycogen storage disease type Ia

The US Food and Drug Administration (FDA) granted accelerated approval for Ultragenyx Pharmaceutical’s Genglycos (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and paediatric patients eight years and older with glycogen storage disease type Ia (GSDIa).  Dr Eric Crombez, Chief Medical Officer at Ultragenyx, commented: “As our first gene therapy… Read More

#News #Regulatory

#Mereo BioPharma #Mergers and acquisitions #Rare disease #Sentynl Therapeutics

Sentynl expands rare disease portfolio with alvelestat purchase

Sentynl Therapeutics and Mereo BioPharma have entered into an option and license agreement for the US commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).   Alvelestat is a neutrophil elastase inhibitor being readied for Phase III and, if approved, would be the first oral treatment… Read More

#Business & Investment #News

Investment concept
#Investment #Rare disease #Spruce Biosciences

Charities donate $5.5m to expand access to rare disease treatment

Cure Sanfilippo Foundation and the National MPS Society have agreed a combined $5.5 million strategic investment in Spruce Biosciences, which will go towards the Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B (or MPS IIIB) Expanded Access Program (EAP).  Samir Gharib, President and Chief Financial Officer of… Read More

#Business & Investment #News

Rare diseases
#FDA #Golden Triangle #Investment #Priority Review #Rare disease #SynaptixBio #UK pharma

Rare disease biotech investment grows but UK lags

Investment in rare disease biotechs has increased following renewal of the FDA’s Priority Review Voucher (PRV) programme, according to SynaptixBio, but the United States remains dominant compared to the UK. In February 2026, the PRV programme was signed into law and will remain in place until reviewed again in September… Read More

#News

#BioCryst Pharmaceuticals #Drug discovery #Rare disease

BioCryst winds down internal discovery programmes

BioCryst Pharmaceuticals has announced plans to discontinue its internal discovery programmes and close its Discovery Center of Excellence facility in Birmingham, Alabama by the end of 2026.  The company says the moves are part of an ongoing strategic evolution to strengthen its rare disease pipeline.   It has determined that prioritising… Read More

#Business & Investment #News

#Base editing #Beam Therapeutics #FDA #Gene editing #Gene therapy #Rare disease

FDA clears base editing therapy for phenylketonuria

The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for Beam Therapeutics’ BEAM-304 for the treatment of phenylketonuria (PKU).   PKU is a rare, inherited metabolic disorder that results in toxic accumulation of phenylalanine (Phe), leading to serious neurologic and neurocognitive impairments and requires strict,… Read More

#News #Regulatory #Trending News

#Cancer research #Clinical trial #Drug discovery #Francis Crick Institute #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

DDW Highlights: 16 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed anti-IL-1β drugs could prevent lung cancer. Elsewhere, the… Read More

#Podcasts

GSK offices
#European Medicines Agency #FDA #GSK #Orphan drugs #Rare disease

JAK inhibitor for VEXAS syndrome gets orphan drug designations

GSK’s momelotinib, a JAK inhibitor with a differentiated mechanism of action, has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome.   VEXAS syndrome is a clonal myeloid disorder with… Read More

#News #Regulatory

#Cancer research #Clinical trial #Drug discovery #Funding #Genetic profiling #GLP-1 #Lung cancer #MHRA #National Institute for Health and Care Research #Obesity #Oncology #Rare disease #Regulatory #The Francis Crick Institute #The Royal Marsden NHS Foundation Trust #University College London #Weight loss

This week in Drug Discovery (8 – 12 June) 

News round-up for 8 – 12 June by Bruno Quinney, Content Team at DDW.  This week, new research suggests anti-IL-1β drugs could prevent lung cancer. Elsewhere, the UK is set to benefit from specialised blood tests and funding for researchers.   The top stories:   … Read More

#News

FDA headquarters
#Clinical trials #MHRA #Rare disease #Regulatory #SynaptixBio

UK should offer US-style incentives in rare diseases, says biotech

The UK Medicines & Healthcare Regulatory Agency (MHRA) is consulting on a new regulatory framework for bringing rare disease drugs more quickly to market.  The new Rare Disease Therapies Regulatory Framework is intended to “support earlier, more frequent, and iterative engagement with developers, providing structured regulatory flexibility where conventional approaches… Read More

#News #Regulatory